A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

2024-519010-31-00 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 8 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 80
Countries 1
Sites 8

High-Risk, Surgically Resectable Melanoma

Key facts

Sponsor
Fondazione Melanoma Onlus
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2025-09-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

High-Risk, Surgically Resectable Melanoma

VersionLevelCodeTermSystem organ class
26.0 LLT 10088049 Cutaneous melanoma 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fondazione Melanoma Onlus

3 Total trials 2 Recruiting
Academic / Non-commercial
Sponsor organisation
Fondazione Melanoma Onlus
Address
Via Mariano Semmola
City
Naples
Postcode
80131
Country
Italy

Scientific contact point

Organisation
Fondazione Melanoma Onlus
Contact name
Medical Monitor

Public contact point

Organisation
Fondazione Melanoma Onlus
Contact name
Medical Monitor

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Authorised, recruitment pending 80 8
Rest of world 0

Investigational sites

Italy

8 sites · Authorised, recruitment pending
Istituto Oncologico Veneto
UOC Oncologia 2, Via Gattamelata 64, 35128, Padova
Fondazione IRCCS Istituto Nazionale Dei Tumori
SS Oncologia Medica Melanomi, Via Giacomo Venezian 1, 20133, Milan
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
SSD di Immunoterapia, Via Piero Maroncelli 40, 47014, Meldola
I.F.O. Istituti Fisioterapici Ospitalieri
UOSD Sarcomi e Tumori Rari, Via Elio Chianesi N 53, 00144, Rome
Istituto Europeo Di Oncologia S.r.l.
Divisione Sviluppo Nuovi Farmaci per Terapie Innovative, Via Giuseppe Ripamonti 435, 20141, Milan
Hospital Santa Maria Della Misericordia
SC Oncologia Medica, Piazzale Giorgio Menghini 1, 06129, Perugia
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Melanoma. Cancer Immunotherapy and Development Therapeutics Unit, Via Mariano Semmola 52, 80131, Naples
Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli
UOC Oncoematologia, Via Sergio Pansini 5, 80131, Naples

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-05-21 Italy Acceptable
2025-09-15
2025-09-15
2 SUBSTANTIAL MODIFICATION SM-1 2026-02-09 Italy Acceptable
2026-03-23
2026-04-20